average weight loss glp-1 drugs Medications for Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Products - Data Briefs -
Description
Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a DPP-IV inhibitor, according to findings published in Thyroid
[DOI] [PubMed] [Google Scholar] 607.Zhang Y., Parajuli K.R., Fava G.E., Gupta R., Xu W., Nguyen L.U
Other groups have demonstrated that chronic systemic GIPR antagonism produces a moderate 69,70 to null 66 effect on body weight in obese mice, suggesting this is not an efficacious mechanism to pursue alone
This is a built-in safety mechanism that distinguishes GLP-1 receptor agonists from older diabetes medications
